Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study

Alexander M. Lesokhin; Richard LeBlanc; Meletios A Dimopoulos; Marcelo Capra; Carmelo Carlo‐Stella; Lionel Karlin; Jean‐François Castilloux; Peter A. Forsberg; Gurdeep Parmar; Axel Tosikyan; Luděk Pour; Vincent Ribrag; Rossella Ribolla; Al‐Ola Abdallah; Nadia Le Roux; Liyan Dong; Helgi van de Velde; Laurent Mayrargue; Lucie Lépine; Sandrine Macé; Philippe Moreau

doi:10.1002/cam4.5753

Related publications

Article2019

Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design

Philippe Moreau, Meletios A Dimopoulos, Kwee Yong, Joseph Mıkhael, Marie‐Laure Risse, Gaëlle Asset, Thomas Martin

Article2025

Efficacy and safety of isatuximab subcutaneous (SC) plus carfilzomib and dexamethasone (Isa-Kd) in patients with relapsed/refractory multiple myeloma (RRMM): Results of the phase 2 study IZALCO.

Gurdeep Parmar, Marcelo Capra, Fernanda Salles Seguro, Vânia Hungria, Meletios A Dimopoulos, Sosana Delimpasi, Jiří Minařík, Luděk Pour, Graça Esteves, Kazutaka Sunami, Junichiro Yuda, Ivan Spicka, Roman Hájek, Christine Soufflet, Disa Yu, Vera Hermina Kalika Koch, Florence Suzan, Hang Quach

Article2020

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Meletios A Dimopoulos, Sara Galimberti, P. Anttila, Marcelo Capra, Michèle Cavo, Craig E. Cole, Cristina Gasparetto, Vânia Hungria, Matthew Jenner, Vladimir Vorobyev, Eduardo Yañez Ruiz, Jian Yin, Rao Saleem, Maeva Hellet, Sandrine Macé, Bruno Paiva, Ravi Vij

Article2023

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

Thomas G. Martin, Meletios A Dimopoulos, Joseph Mıkhael, Kwee Yong, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martínez, Chang‐Ki Min, Luděk Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, France Casca, Sandrine Macé, Marie‐Laure Risse, Philippe Moreau

Article2020

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

Joseph Mıkhael, Joshua Richter, Ravi Vij, Craig E. Cole, Jeffrey A. Zonder, Jonathan L. Kaufman, William Bensinger, Meletios A Dimopoulos, Nikoletta Lendvai, Parameswaran Hari, Enrique M. Ocio, Cristina Gasparetto, Shaji Kumar, Corina Oprea, Marielle Chiron, Claire Brillac, Éric Charpentier, Jesús F. San Miguel, Thomas G. Martin